Follow
Michele Moschetta, MD PhD
Michele Moschetta, MD PhD
Executive Director, Early Clinical Development Oncology, AstraZeneca
Verified email at astrazeneca.com
Title
Cited by
Cited by
Year
Targeting the bone marrow microenvironment in multiple myeloma
Y Kawano, M Moschetta, S Manier, S Glavey, GT Görgün, AM Roccaro, ...
Immunological reviews 263 (1), 160-172, 2015
3872015
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
YT Tai, C Acharya, G An, M Moschetta, MY Zhong, X Feng, M Cea, ...
Blood, The Journal of the American Society of Hematology 127 (25), 3225-3236, 2016
3072016
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
M Moschetta, A George, SB Kaye, S Banerjee
Annals of Oncology 27 (8), 1449-1455, 2016
3002016
Engineered nanomedicine for myeloma and bone microenvironment targeting
A Swami, MR Reagan, P Basto, Y Mishima, N Kamaly, S Glavey, S Zhang, ...
Proceedings of the National Academy of Sciences 111 (28), 10287-10292, 2014
2822014
Metabolic signature identifies novel targets for drug resistance in multiple myeloma
P Maiso, D Huynh, M Moschetta, A Sacco, Y Aljawai, Y Mishima, ...
Cancer research 75 (10), 2071-2082, 2015
2442015
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
AM Roccaro, A Sacco, C Jimenez, P Maiso, M Moschetta, Y Mishima, ...
Blood, The Journal of the American Society of Hematology 123 (26), 4120-4131, 2014
2252014
SDF-1 inhibition targets the bone marrow niche for cancer therapy
AM Roccaro, A Sacco, WG Purschke, M Moschetta, K Buchner, C Maasch, ...
Cell reports 9 (1), 118-128, 2014
1602014
Therapeutic targeting of the mTOR‐signalling pathway in cancer: benefits and limitations
M Moschetta, A Reale, C Marasco, A Vacca, MR Carratù
British journal of pharmacology 171 (16), 3801-3813, 2014
1382014
CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation
AM Roccaro, Y Mishima, A Sacco, M Moschetta, YT Tai, J Shi, Y Zhang, ...
Cell reports 12 (4), 622-635, 2015
1372015
The developing story of predictive biomarkers in colorectal cancer
S Boussios, MA Ozturk, M Moschetta, A Karathanasi, ...
Journal of personalized medicine 9 (1), 12, 2019
1322019
The cancer glycome: carbohydrates as mediators of metastasis
SV Glavey, D Huynh, MR Reagan, S Manier, M Moschetta, Y Kawano, ...
Blood reviews 29 (4), 269-279, 2015
1272015
Role of endothelial progenitor cells in cancer progression
M Moschetta, Y Mishima, I Sahin, S Manier, S Glavey, A Vacca, ...
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (1), 26-39, 2014
1252014
The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma
SV Glavey, S Manier, A Natoni, A Sacco, M Moschetta, MR Reagan, ...
Blood, The Journal of the American Society of Hematology 124 (11), 1765-1776, 2014
1212014
Combined strategies with poly (ADP-Ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review
S Boussios, P Karihtala, M Moschetta, A Karathanasi, A Sadauskaite, ...
Diagnostics 9 (3), 87, 2019
1122019
Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies
MA Frassanito, L Rao, M Moschetta, R Ria, L Di Marzo, A De Luisi, ...
Leukemia 28 (4), 904-916, 2014
1112014
Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin–positive metastatic human melanoma xenografts
M Moschetta, F Pretto, A Berndt, K Galler, P Richter, A Bassi, P Oliva, ...
Cancer research 72 (7), 1814-1824, 2012
1112012
Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond
S Boussios, C Abson, M Moschetta, E Rassy, A Karathanasi, T Bhat, ...
Drugs in R&D 20, 55-73, 2020
1092020
Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression
Y Kawano, O Zavidij, J Park, M Moschetta, K Kokubun, TH Mouhieddine, ...
The Journal of clinical investigation 128 (6), 2487-2499, 2018
972018
Antibody dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab.
K AT, G SV, B NA, J A, G JL, M S, M M, M Y, R A, D A, L CJ, S A, H D, T YT, ...
Mol Cancer Ther., 2018
932018
Proteomic characterization of human multiple myeloma bone marrow extracellular matrix
SV Glavey, A Naba, S Manier, K Clauser, S Tahri, J Park, MR Reagan, ...
Leukemia 31 (11), 2426-2434, 2017
912017
The system can't perform the operation now. Try again later.
Articles 1–20